For the health and hope of human

Committed to the research and development, production and professional promotion of innovative drugs and difficult generic drugs

For the health and hope of human

Committed to the research and development, production and professional promotion of innovative drugs and difficult generic drugs

For the health and hope of human

Committed to the research and development, production and professional promotion of innovative drugs and difficult generic drugs

About Jiexi
A comprehensive pharmaceutical enterprise integrating research and development, production and sales
Founded in 2019 and headquartered in Hefei, Anhui Province, the company is a comprehensive pharmaceutical enterprise integrating research and development, production and sales, focusing on cardiovascular, anti-infection, digestive system, respiratory system, nervous system and other disease treatment fields.
The company adheres to the idea of independent research and development, trains and introduces high-level technical personnel, and has a high-quality R & D team in Beijing and Hefei R & D center.
The Beijing R&D Center mainly carries out the research and development of innovative drugs and apis. Innovative drug research and development focuses on the discovery and development of new antibacterial drugs, especially the development of new mechanisms and new target drugs for resistant bacteria such as ESKAPE. API research and development focuses on the development of synthetic processes for highly difficult generic API.
2019
Established in
40+
Existing staff
11
Approved generic drugs
Focus on building cardiovascular and cerebrovascular, divine, infection, respiration and digestion and other fields

Metabolic field
Cardiovascular field
Central nervous field
Anti-infection field
Central nervous field
Topiramate Tablets  100mg
SFDA approval number H20213669
Adapt to disease: Epilepsy
Topiramate Tablets100mg
Central nervous field
Topiramate Tablets  25mg
SFDA approval number H20213668
Adapt to disease: Epilepsy
Topiramate Tablets25mg
Cardiovascular field
Valsartan and Amlodipine Tablets(I)  80mg:5mg
SFDA approval number H20223085
Adapt to disease: Essential hypertension
Valsartan and Amlodipine Tablets(I)80mg:5mg
Cardiovascular field
Metoprolol Succinate Sustained-release Tablets  23.75mg
SFDA approval number H20213592
Adapt to disease: Hypertension, angina, chronic heart failure
Metoprolol Succinate Sustained-release Tablets23.75mg
Cardiovascular field
Metoprolol Succinate Sustained-release Tablets  47.5mg
SFDA approval number H20213593
Adapt to disease: Hypertension, angina, chronic heart failure
Metoprolol Succinate Sustained-release Tablets47.5mg
Cardiovascular field
Indapamide Sustained-Release Tablets  1.5mg
SFDA approval number H20213537
Adapt to disease: Adult essential hypertension
Indapamide Sustained-Release Tablets1.5mg
Metabolic field
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅲ)  2.5mg:1000mg
SFDA approval number H20234335
Adapt to disease: Adult type 2 diabetes
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅲ)2.5mg:1000mg
Metabolic field
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ)  5mg:1000mg
SFDA approval number H20234334
Adapt to disease: Adult type 2 diabetes
Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (Ⅰ)5mg:1000mg
News
Always share with you our little things
2024-07-04
2024 CPHI International Public
On June 21, 2024, 2024CPHI International Public Procurement Forum for Medical Products was...
2024-07-03
Innovation + sea two-wheel dri
On the afternoon of June 19, on the occasion of the 22nd CPHI World Pharmaceutical Raw Mat...
2024-05-09
Further upgrading of the synth
Bio-manufacturing, as the most representative new quality productivity, achieves key and s...
2024-03-26
Innovative drugs "patent
In recent years, under the catalysis of consistent evaluation, centralized procurement, MA...